Controlled transscleral drug delivery formulations to the eye: Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis

Fernando Paganelli, José A. Cardillo, Alessandro R J Dare, Luiz A S Melo, David R. Lucena, Arnobio A. Silva, Anselmo G. Oliveira, Antonio C. Pizzolitto, Daniel Lavinsky, Mirian Skaf, Accio A. Souza-Filho, Ana L. Hfling-Lima, Quan Dong Nguyen, Baruch D. Kuppermann, Rocio Herrero-Vanrell, Rubens Belfort

Research output: Contribution to journalArticle

Abstract

Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.

Original languageEnglish (US)
Pages (from-to)955-965
Number of pages11
JournalExpert Opinion on Drug Delivery
Volume7
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Drug Compounding
Anti-Inflammatory Agents
Pharmaceutical Preparations
Inflammation
Eye Infections
Topical Administration
Sclera
Endophthalmitis
Therapeutics
Patient Compliance
Anti-Infective Agents
Cataract
Permeability
Steroids

Keywords

  • Antibiotics
  • Antimicrobials
  • Cataract surgery
  • Endophthalmitis
  • Eye drops
  • Eye infections
  • Intraocular penetration
  • Ocular drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Controlled transscleral drug delivery formulations to the eye : Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. / Paganelli, Fernando; Cardillo, José A.; Dare, Alessandro R J; Melo, Luiz A S; Lucena, David R.; Silva, Arnobio A.; Oliveira, Anselmo G.; Pizzolitto, Antonio C.; Lavinsky, Daniel; Skaf, Mirian; Souza-Filho, Accio A.; Hfling-Lima, Ana L.; Nguyen, Quan Dong; Kuppermann, Baruch D.; Herrero-Vanrell, Rocio; Belfort, Rubens.

In: Expert Opinion on Drug Delivery, Vol. 7, No. 8, 08.2010, p. 955-965.

Research output: Contribution to journalArticle

Paganelli, F, Cardillo, JA, Dare, ARJ, Melo, LAS, Lucena, DR, Silva, AA, Oliveira, AG, Pizzolitto, AC, Lavinsky, D, Skaf, M, Souza-Filho, AA, Hfling-Lima, AL, Nguyen, QD, Kuppermann, BD, Herrero-Vanrell, R & Belfort, R 2010, 'Controlled transscleral drug delivery formulations to the eye: Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis', Expert Opinion on Drug Delivery, vol. 7, no. 8, pp. 955-965. https://doi.org/10.1517/17425247.2010.498817
Paganelli, Fernando ; Cardillo, José A. ; Dare, Alessandro R J ; Melo, Luiz A S ; Lucena, David R. ; Silva, Arnobio A. ; Oliveira, Anselmo G. ; Pizzolitto, Antonio C. ; Lavinsky, Daniel ; Skaf, Mirian ; Souza-Filho, Accio A. ; Hfling-Lima, Ana L. ; Nguyen, Quan Dong ; Kuppermann, Baruch D. ; Herrero-Vanrell, Rocio ; Belfort, Rubens. / Controlled transscleral drug delivery formulations to the eye : Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. In: Expert Opinion on Drug Delivery. 2010 ; Vol. 7, No. 8. pp. 955-965.
@article{f064dfc5b8214d6f80940ba2fadd4049,
title = "Controlled transscleral drug delivery formulations to the eye: Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis",
abstract = "Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.",
keywords = "Antibiotics, Antimicrobials, Cataract surgery, Endophthalmitis, Eye drops, Eye infections, Intraocular penetration, Ocular drug delivery",
author = "Fernando Paganelli and Cardillo, {Jos{\'e} A.} and Dare, {Alessandro R J} and Melo, {Luiz A S} and Lucena, {David R.} and Silva, {Arnobio A.} and Oliveira, {Anselmo G.} and Pizzolitto, {Antonio C.} and Daniel Lavinsky and Mirian Skaf and Souza-Filho, {Accio A.} and Hfling-Lima, {Ana L.} and Nguyen, {Quan Dong} and Kuppermann, {Baruch D.} and Rocio Herrero-Vanrell and Rubens Belfort",
year = "2010",
month = "8",
doi = "10.1517/17425247.2010.498817",
language = "English (US)",
volume = "7",
pages = "955--965",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Controlled transscleral drug delivery formulations to the eye

T2 - Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis

AU - Paganelli, Fernando

AU - Cardillo, José A.

AU - Dare, Alessandro R J

AU - Melo, Luiz A S

AU - Lucena, David R.

AU - Silva, Arnobio A.

AU - Oliveira, Anselmo G.

AU - Pizzolitto, Antonio C.

AU - Lavinsky, Daniel

AU - Skaf, Mirian

AU - Souza-Filho, Accio A.

AU - Hfling-Lima, Ana L.

AU - Nguyen, Quan Dong

AU - Kuppermann, Baruch D.

AU - Herrero-Vanrell, Rocio

AU - Belfort, Rubens

PY - 2010/8

Y1 - 2010/8

N2 - Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.

AB - Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.

KW - Antibiotics

KW - Antimicrobials

KW - Cataract surgery

KW - Endophthalmitis

KW - Eye drops

KW - Eye infections

KW - Intraocular penetration

KW - Ocular drug delivery

UR - http://www.scopus.com/inward/record.url?scp=77954876943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954876943&partnerID=8YFLogxK

U2 - 10.1517/17425247.2010.498817

DO - 10.1517/17425247.2010.498817

M3 - Article

C2 - 20645672

AN - SCOPUS:77954876943

VL - 7

SP - 955

EP - 965

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 8

ER -